

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
09/820,328	03/29/2001	Andrzej Kilian	076518-0140			
75	90 07/16/2002					
Richard C. Peet			EXAMI	NER		
FOLEY & LAR			LU, FRANK	LU, FRANK WEI MIN		
Washington Ha						
3000 K Street, N.W., Suite 500 Washington, DC 20007-5109			ART UNIT	PAPER NUMBER		
washington, D	20007 2107		1634	1,		
			DATE MAILED: 07/16/2002	l)		

Please find below and/or attached an Office communication concerning this application or proceeding.

•		Applicat	tion No.	Applicant(s)	
		09/820,	328	KILIAN, ANDRZEJ	
	Office Action Summary	Examine	er	Art Unit	
		Frank W	/ Lu	1634	
Period fo	The MAILING DATE of this communion Reply	cation appears on ti	he cover sheet with t	he correspondence address	•
THE - External after - If the - If NO - Failt - Any	ORTENED STATUTORY PERIOD FOR MAILING DATE OF THIS COMMUNIONS on Soft time may be available under the provisions SIX (6) MONTHS from the mailing date of this common period for reply specified above is less than thirty (30) period for reply is specified above, the maximum stature to reply within the set or extended period for reply reply received by the Office later than three months a ed patent term adjustment. See 37 CFR 1.704(b).	CATION. of 37 CFR 1.136(a). In no e unication.)) days, a reply within the st itutory period will apply and will, by statute, cause the ap	event, however, may a reply atutory minimum of thirty (30 will expire SIX (6) MONTHS oplication to become ABAND	be timely filed) days will be considered timely. from the mailing date of this communicat ONED (35 U.S.C. § 133).	tion.
1)⊠	Responsive to communication(s) file	ed on <u>25 April 2002</u>	! .		
2a) <u></u> □	This action is FINAL .	2b)⊠ This action i	is non-final.		
3)□	Since this application is in condition closed in accordance with the pract				s is
·	ion of Claims				
4)⊠	Claim(s) <u>1-40</u> is/are pending in the	• •			
- \	4a) Of the above claim(s) 23-40 is/ar	e withdrawn from co	onsideration.		
·	Claim(s) <u>1-22</u> is/are allowed.				
6)[_	Claim(s) is/are rejected.				
7)[_]	Claim(s) is/are objected to.				
	Claim(s) are subject to restric	tion and/or election	requirement.		
	ion Papers	- F			
	The specification is objected to by the			to be the Fee See	
10)🖂	The drawing(s) filed on 3/29/01 (original April 2014)			•	
44)	Applicant may not request that any obj				
11)[The proposed drawing correction filed			pproved by the Examiner.	
12)□	If approved, corrected drawings are re-		Office action.		
•	The oath or declaration is objected to	by the Examiner.			
	under 35 U.S.C. §§ 119 and 120			40() () ()	
-	Acknowledgment is made of a claim	for foreign priority i	under 35 U.S.C. § 1	19(a)-(d) or (t).	
a)	All b) Some * c) None of:				
	1. Certified copies of the priority				
	2. Certified copies of the priority				
* ;	 Copies of the certified copies application from the Intern See the attached detailed Office actio 	ational Bureau (PC	T Rule 17.2(a)).	-	
14)🛛	Acknowledgment is made of a claim for	or domestic priority	under 35 U.S.C. § 1	19(e) (to a provisional applic	ation).
•	a) \square The translation of the foreign lar	•	-		•
	Acknowledgment is made of a claim f				
Attachme	nt(s)				
2) X Noti	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (F rmation Disclosure Statement(s) (PTO-1449) P			nmary (PTO-413) Paper No(s) rmal Patent Application (PTO-152)	- ·

Application/Control Number: 09/820,328 Page 2

Art Unit: 1634

DETAILED ACTION

Election/Restriction

1. Applicant's election with traverse of Group I, claims 1-22, species plant in claim 19, and species rice in claim 20 in Paper No. 9 is acknowledged. The traversal is on the ground(s) that: (1) "there is no undue burden imposed on the examiner to search these allegedly separate Groups."; (2) "[G]roups II, III, IV, and V are all classified in the exact same subclass," (3) "[G]roup II and III are drawn to exactly the same invention," while "[G]roups IV and V are both drawn to the same invention,"; (4) "[E]ach member of the Markush group recited in claim 20 share a common utility in that each organism recited in claim 20 is used as source from which a diversity panel can be made according to the method of claim 1."; and (5) "election of a single species as required by the examiner, in addition to being improper as a matter of examination procedure, is nonsensical and would alter the objection of the claimed invention."

The above arguments have been fully considered and have not been found persuasive toward the withdrawal of the restriction requirement nor persuasive toward the relaxation of same such that Groups I to VI will be examined. First, restriction requirement was not based on classifications of Groups II, III, IV, and V. Second, as shown in previous office action in Paper No: 7, the examiner clearly explained that different and distinct searches were required for each restriction groups (see previous office action). Therefore, there will be undue burden imposed on the examiner to search all groups. Third, MPEP § 803.02 states that "[I]f the members of the Markush group are sufficiently few in number or so closely related that a search and examination of the entire claim can be made without serious burden, the examiner must examine all the

Page 3

Art Unit: 1634

Application/Control Number: 09/820,328

members of the Markush group in the claim on the merits, even though they are directed to independent and distinct inventions.". However, 6 different organisms in claim 19 and 18 different plant in claim 20 are not few in number or are not so closely related. For example, species in claim 19 are different organisms. Fourth, each member of the Markush group recited in claim 20 does not share a common utility since these plants have different structural features (rice is different from apple) (See MPEP § 803.02). Fifth, election of a single species would not alter the objection of the claimed invention since a first diversity panel in step (a) of claim 1 could be from nucleic acids of two or more identical organisms (see claim 18).

Therefore, the requirement is still deemed proper and is therefore made FINAL.

Sequence Rules Compliance

This application contains sequence disclosures that are encompassed by the definitions 2. for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Direct the reply to the undersigned.

Conclusion

Claims 1-22 appears to be allowable since, during the prior art search, there was no prior 3. art that taught all limitations recited in claim 1.

Application/Control Number: 09/820,328 Page 4

Art Unit: 1634

4. Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notices published in the Official Gazette, 1096 OG 30 (November 15, 1988), 1156 OG 61 (November 16, 1993), and 1157 OG 94 (December 28, 1993)(See 37 CAR § 1.6(d)). The CM Fax Center number is either (703) 308-4242 or (703)305-3014.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Frank Lu, Ph.D., whose telephone number is (703) 305-1270. The examiner can normally be reached on Monday-Friday from 9 A.M. to 5 P.M.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, W. Gary Jones, can be reached on (703) 308-1152.

Any inquiry of a general nature or relating to the status of this application should be directed to the patent Analyst of the Art Unit, Ms. Chantae Dessau, whose telephone number is (703) 605-1237.

Frank Lu July 12, 2002

ETHAN C. WHISENANT PRIMARY EXAMINER

Application No.: 09/820,328

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

	This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
X 2	This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
X 3	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	7. Other:
Δnı	plicant Must Provide:
X	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
X	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
Fo	r questions regarding compliance to these requirements, please contact
Fo Fo	r Rules Interpretation, call (703) 308-4216 or CRF Submission Help, call (703) 308-4212 or PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE